Blar i NTNU Open på forfatter "Brustugun, Odd Terje"
-
Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer
Halvorsen, Tarje Onsøien; Sundstrøm, Stein Harald; Fløtten, Øystein; Brustugun, Odd Terje; Brunsvig, Paal Fr.; Aasebø, Ulf; Bremnes, Roy M.; Kaasa, Stein; Grønberg, Bjørn Henning (Journal article; Peer reviewed, 2016)Background: Many patients with limited disease small cell lung cancer (LD SCLC) suffer from comorbidity. Not all patients with comorbidity are offered standard treatment, though there is little evidence for such a policy. ... -
Concordance between clinical and pathology TNM-staging in lung cancer
Solberg, Steinar; Nilssen, Yngvar; Brustugun, Odd Terje; Haram, Per Magnus; Helland, Åslaug; Møller, Bjørn; Strand, Trond-Eirik; Wahl, Sissel Gyrid Freim; Fjellbirkeland, Lars (Peer reviewed; Journal article, 2022)Objectives - A prerequisite for utilizing the tumour, lymph-nodes, and metastases (TNM) for the staging of lung cancer patients is a high quality of the reported data on which the staging is based. The aim of this study ... -
Expression of estrogen receptor-α and survival in advanced-stage non-small cell lung cancer
Lund-Iversen, Marius; Scott, Helge; Strøm, Erik Heyerdahl; Theiss, Noah; Brustugun, Odd Terje; Grønberg, Bjørn Henning (Journal article; Peer reviewed, 2018)Background/Aim: The favorable prognosis of women with non-small-cell lung cancer (NSCLC) compared to men might be explained by sex hormone-related mechanisms. We investigated whether this observation could be explained by ... -
Increase in curative treatment and survival of lung cancer in Norway 2001-2016
Solberg, Steinar; Nilssen, Yngvar; Brustugun, Odd Terje; Grimsrud, Tom Kristian; Haram, Per Magnus; Helbekkmo, Nina; Helland, Åslaug; Hjelde, Harald Harris; Jakobsen, Bjørn; Møller, Bjørn; Petersen, Martin; Strand, Trond-Eirik; Wahl, Sissel Gyrid Freim; Aanerud, Marianne; Fjellbirkeland, Lars (Peer reviewed; Journal article, 2019)We have studied the alterations in the use of curative treatment and the outcome for lung cancer patients in Norway 2001–2016. The Cancer Registry of Norway has a practically complete registration of all cancer diagnoses, ... -
Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study
Eide, Inger Johanne; Grut, Harald; Helland, Åslaug; Ekman, Simon; Sørensen, Jens Benn; Hansen, Karin Holmskov; Grønberg, Bjørn Henning; Cicenas, Saulius; Koivunen, Jussi Pekka; Mellemgaard, Anders; Brustugun, Odd Terje (Peer reviewed; Journal article, 2021)Introduction Osimertinib is effective for relapsed T790M-positive patients with brain metastases. The high brain permeability suggests that also such patients without T790M could benefit. Therefore, we evaluated the effect ... -
Mutasjonstesting ved ikke-småcellet lungekreft
Brustugun, Odd Terje; Helland, Åslaug; Fjellbirkeland, Lars; Kleinberg, Lilach; Ariansen, Sarah Louise; Jebsen, Peter Wilhelm; Scott, Helge; Dønnem, Tom; Bremnes, Roy M.; Berg, Thomas; Grønberg, Bjørn Henning; Dai, Hong Yan; Wahl, Sissel Gyrid Freim; Mangseth, Kjersti; Helgeland, Lars (Peer reviewed; Journal article, 2012)BAKGRUNN. Epidermal vekstfaktor-reseptor (EGFR) tyrosinkinasehemmere (EGFR-TKI) er en relativt ny klasse legemidler til behandling av ikke-småcellet lungekreft. Den nasjonale faggruppen for lungekreft, Norsk Lunge Cancer ... -
Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
Eide, Inger Johanne Zwicky; Stensgaard, Simone; Helland, Åslaug; Ekman, Simon; Mellemgaard, Anders; Hansen, Karin Holmskov; Cicenas, Saulius; Koivunen, Jussi; Grønberg, Bjørn Henning; Sørensen, Boe Sandahl; Brustugun, Odd Terje (Peer reviewed; Journal article, 2022)Background: Osimertinib is standard of care for EGFR-mutated non-small cell lung cancer (NSCLC) patients. The efficacy of the drug in patients with mutations other than the common deletion in exon 19 and L858R in exon 21 ... -
Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
Eide, Inger Johanne; Helland, Åslaug; Ekman, Simon; Mellemgaard, Anders; Hansen, Karin Holmskov; Cicenas, Saulius; Koivunen, Jussi; Grønberg, Bjørn Henning; Brustugun, Odd Terje (Peer reviewed; Journal article, 2020)Objectives In non-small cell lung cancer patients with acquired resistance to first- or second-generation EGFR-TKIs, osimertinib is approved in the presence of the T790 M resistance mutation. We assessed the efficacy of ... -
Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer
Killingberg, Kristin Toftaker; Halvorsen, Tarje Onsøien; Fløtten, Øystein; Brustugun, Odd Terje; HORNSLIEN, KJERSTI; Madebo, Tesfaye; Langer, Seppo W.; Schytte, Tine; Risum, Signe; Tsakonas, Georgios; Nyman, Jan; Engleson, Jens; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2022)Objectives In a randomized phase II trial, twice daily (BID) thoracic radiotherapy (TRT) of 60 Gy/40 fractions improved survival compared with 45 Gy/30 fractions in limited stage small-cell lung cancer (LS SCLC). Notably, ... -
Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer
Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Fløtten, Øystein; Brustugun, Odd Terje; Brunsvig, Paal Fr.; Aasebø, Ulf; Bremnes, Roy M.; Tollåli, Terje; Hornslien, Kjersti; Aksnessæther, Bjørg Y.; Liaaen, Erik Dyb; Sundstrøm, Stein Harald (Journal article; Peer reviewed, 2016)Background: Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited disease small cell lung cancer (LD SCLC). Twice daily TRT is well documented, but not universally implemented – probably mainly ... -
Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC
Halvorsen, Tarje Onsøien; Stokke, Kristin; Killingberg, Kristin Toftaker; Raj, Sunil Xavier; Sørhaug, Sveinung; Brustugun, Odd Terje; Fløtten, Øystein; Helbekkmo, Nina; Hornslien, Kjersti; Madebo, Tesfaye; Fluge, Sverre; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2020)Objectives: Two phase III trials show that maintenance pemetrexed therapy after platinum-doublet chemotherapy prolongs overall survival (OS) and progression free survival (PFS) in advanced non-squamous non-small-cell lung ... -
Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016
Brustugun, Odd Terje; Grønberg, Bjørn Henning; Fjellbirkeland, Lars; Helbekkmo, Nina; Aanerud, Marianne; Grimsrud, Tom Kristian; Helland, Åslaug; Møller, Bjørn; Nilssen, Yngvar; Strand, Trond-Eirik; Solberg, Steinar (Journal article; Peer reviewed, 2018)Introduction There have been significant changes in both diagnostic procedures and therapy for lung cancer since the beginning of the millennium. National incidence and survival data from 2000 through 2016 are ... -
Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement
Valan, Christine Damgaard; Slagsvold, Jens Erik; Halvorsen, Tarje Onsøien; Herje, Martin; Bremnes, Roy M.; Brunsvig, Paal Fr.; Brustugun, Odd Terje; Fløtten, Øystein; Levin, Nina; Sundstrøm, Stein Harald; Grønberg, Bjørn Henning (Journal article; Peer reviewed, 2018)Background/Aim: There are several definitions of limited disease (LD) in small cell lung cancer (SCLC), differing with respect to N3 disease accepted. We analyzed patients from a randomized trial comparing two schedules ... -
Tracheal cancer: a rare and deadly but potentially curable disease that also affects younger people
Nilssen, Yngvar; Solberg, Steinar; Brustugun, Odd Terje; Møller, Bjørn; Sundset, Arve; Wahl, Sissel Gyrid Freim; Helland, Åslaug (Peer reviewed; Journal article, 2023)OBJECTIVES The incidence of tracheal cancer is low, few clinicians get much experience and the awareness may be low. Recent data on the treatment and outcome are limited. The aim of the present study was to present ... -
Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer
Halvorsen, Tarje Onsøien; Herje, Martin; Levin, Nina; Bremnes, Roy M.; Brustugun, Odd Terje; Fløtten, Øystein; Kaasa, Stein; Sundstrøm, Stein Harald; Grønberg, Bjørn Henning (Journal article; Peer reviewed, 2016)Objectives Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited disease small-cell lung cancer (LD SCLC). TRT should start as early as possible, often meaning with the second course due to ...